<div><div></div><div>Biofrontera reported first-quarter 2026 revenue of $10.1 million, a 17% increase year-over-year, and gross margins of approximately 80% for the quarter. The company recorded an operating loss of $4.3 million and a net loss of $4.8 million, while adjusted EBITDA improved to $(3.6) million. Cash used in operations was minimal at $70 thousand, leaving cash and cash equivalents of $6.3 million as of March 31, 2026.Financial Highlights<ul><li>Revenue: $10.1 million for Q1 2026, up ~17% versus Q1 2025 ($8.6 million).</li><li>Gross profit margin: Approximately 80% in Q1 2026 (compared with ~62% in Q1 2025).</li><li>Operating loss: $4.3 million for Q1 2026 (loss from operations).</li><li>Net loss: $4.8 million for Q1 2026, or $(0.41) per share.</li><li>Adjusted EBITDA: $(3.6) million for Q1 2026 (Adjusted EBITDA margin of (35.3)%).</li></ul>Business Highlights<ul><li>FDA progress: FDA completed filing review and accepted the supplemental NDA for Ameluz PDT for superficial basal cell carcinoma with a PDUFA target action date of September 28, 2026.</li><li>Clinical program milestones: Positive, statistically significant top-line Phase 3 results for Ameluz PDT in mild to moderate actinic keratoses on extremities, neck and trunk, meeting the primary endpoint.</li><li>Regulatory-enabling study: Database lock achieved for a Phase 1 pharmacokinetics study required for FDA filing on treatment fields up to 240 cm² on extremities, neck and trunk.</li><li>Acne program progress: Positive Phase 2b results for moderate to severe acne vulgaris showing a 58% reduction in inflammatory lesions with a 3-hour incubation Ameluz PDT protocol versus 37% with vehicle PDT (PPS).</li><li>Corporate and commercial updates: Strategic Transaction with Biofrontera AG implemented a new earnout structure that materially lowered cost of goods and supported expanded gross margins; Nasdaq minimum bid price compliance regained on May 6, 2026.</li></ul>Original SEC Filing: Biofrontera Inc. [ BFRI ] - 8-K - May. 14, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

BFRI

Biofrontera reported Q1 2026 revenue of $10.1 million, a 17% increase year-over-year, with gross margins around 80%. The company faced an operating loss of $4.3 million and a net loss of $4.8 million, while adjusted EBITDA improved to $(3.6) million. Cash and cash equivalents stood at $6.3 million. Key highlights include FDA acceptance of a supplemental NDA for Ameluz PDT and positive Phase 3 results for actinic keratoses. A strategic transaction with Biofrontera AG improved gross margins and compliance with Nasdaq minimum bid price was regained.

TradingView

Biofrontera

Health Care Select Sector SPDR

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

VG Health

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM)

Biofrontera Reports Q1 2026: Revenue $10.1M, Gross Margin ~80%, Adjusted EBITDA $(3.6) M